Format

Send to

Choose Destination
Clin Infect Dis. 2015 Dec 1;61(11):1703-6. doi: 10.1093/cid/civ638. Epub 2015 Jul 28.

Association of immune response to endothelial cell growth factor with early disseminated and late manifestations of Lyme disease but not posttreatment Lyme disease syndrome.

Author information

1
Department of Medicine, Columbia University Medical Center, New York, New York.
2
MassBiologics, University of Massachusetts Medical School, Boston.
3
Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York.
4
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

Abstract

Endothelial cell growth factor has been recently proposed as a potential autoantigen in manifestations of Lyme disease that are thought to involve immune-mediated mechanisms. Our findings indicate that a humoral immune response to this protein is not associated with posttreatment Lyme disease syndrome.

KEYWORDS:

Borrelia burgdorferi; Lyme disease; antibody; endothelial cell growth factor; posttreatment Lyme disease syndrome

PMID:
26219695
PMCID:
PMC4643484
DOI:
10.1093/cid/civ638
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center